博士，主任药师，博士研究生导师，四川大学华西医院临床药学部（药剂科）学科主任，四川省学术与技术带头人后备人才，四川省卫健委学术与技术带头人。1996年毕业于华西医科大学药学院，获理学学士学位；1996年7月在四川大学华西医院药剂科工作，期间于2006年获四川大学华西药学院药剂学硕士、2010年获四川大学工商管理学院工商管理硕士、2014年获四川大学华西药学院临床药学博士学位。承担或参与科技部重点研发项目、自然科学基金、四川省科技厅、省发改委、省卫生厅等科研课题20余项；以第一或通讯作者发表论文160余篇（其中SCI 30余篇）；出版学术著作10余部，发明专利5项，软件著作权3项。
中国医院协会药事管理专委会副主委，中国抗癌协会肿瘤临床药学专委会副主委，中国药学会循证药学专委会、药学服务专委会委员，中国医药教育协会老年药学专委会副主委，中国研究型医院学会药物评价专委会常委，四川省药学会药事管理专委会主委，成都药学会医院药学专委会主委，《中国医院药学杂志》、《中国药房》、《医药导报》编委等。
主要研究课题：
1.科技部重点研发计划（子项目）：老年人常用药物体内代谢和相互作用动物模型研究平台的建立和应用，编号：2020YFC2008302，负责人；
2.四川省科技厅：功能化量子点靶向干扰Spns2基因对肿瘤转移的影响和机制研究，编号：2018GZ0311，负责人；
3.四川省科技厅：突发事件应急药品保障体系建设与循征评价，编号：2014ZR0080，负责人。
代表论著：
1. Analysis of adverse event of interstitial lung disease in men with prostate cancer receiving hormone therapy using the Food and Drug Administration Adverse Event Reporting System. British Journal of Clinical Pharmacology. 2023; 89(2): 440-448.
2. Sex differences in immune-related adverse events with immune checkpoint inhibitors: data mining of the FDA adverse event eporting system. International Journal of Clinical Pharmacy. 2022; 44(3): 689-697.
3.Predicting adverse drug events in older inpatients: a machine learning study. International Journal of Clinical Pharmacy. 2022; 44(6):1304-1311.
4. The prevalence and risk factors of potentially inappropriate medication use in older Chinese inpatients with multimorbidity and polypharmacy: a cross-sectional study. Annals of Translational Medicine. 2021; 9(18).
5. Immune-related adverse events associated with immune checkpoint inhibitors: An updated comprehensive disproportionality analysis of the FDA adverse event reporting system. International Immunopharmacology. 2021; 95: :107498.
6. Potentially inappropriate medications in Chinese older outpatients in tertiary hospitals according to Beers criteria: A cross-sectional study. International Journal of Clinical Practice. 2021; 75(8):e14348.
7. Validating the Chinese geriatric trigger tool and analyzing adverse drug event associated risk factors in elderly Chinese patients: A retrospective review. Plos One. 2020; 15(4):e0232095
8. The approved gene therapy drugs worldwide: from 1998 to 2019. Biotechnol Adv.2020,40:107502.
9. Validating the Chinese geriatric trigger tool and analyzing adverse drug event associated risk factors in elderly Chinese patients: A retrospective review. PLoS One.2020,15(4):e0232095.
10. Cost-Effectiveness Analysis of Maintenance Olaparib in Patients with Metastatic Pancreatic Cancer and a Germline BRCA1/2 Mutation Based on the POLO Trial. Cancer Manag Res.2020,12:12919-12926.
11. Cost-effectiveness analysis of the addition of bevacizumab to temozolomide therapy for the treatment of unresected glioblastoma. Oncol Lett.2020,19(1):424-430.
12. Cost-effectiveness analysis of ramucirumab treatment for patients with hepatocellular carcinoma who progressed on sorafenib with α-fetoprotein concentrations of at least 400 ng/ml. J Med Econ.2020,23(4):347-352.
研究生部公众号